Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Mar 9;14(6):1845.
doi: 10.3390/jcm14061845.

Current Role of Artificial Intelligence in the Management of Esophageal Cancer

Affiliations
Review

Current Role of Artificial Intelligence in the Management of Esophageal Cancer

Evgenia Mela et al. J Clin Med. .

Abstract

Background/Objectives: Esophageal cancer (EC) represents a major global contributor to cancer-related mortality. The advent of artificial intelligence (AI), including machine learning, deep learning, and radiomics, holds promise for enhancing treatment decisions and predicting outcomes. The aim of this review is to present an overview of the current landscape and future perspectives of AI in the management of EC. Methods: A literature search was performed on MEDLINE using the following keywords: "Artificial Intelligence", "Esophageal cancer", "Barrett's esophagus", "Esophageal Adenocarcinoma", and "Esophageal Squamous cell carcinoma". All titles and abstracts were screened; the results included 41 studies. Results: Over the past five years, the number of studies focusing on the application of AI to the treatment and prognosis of EC has surged, leveraging increasingly larger datasets with external validation. The simultaneous incorporation in AI models of clinical factors and features from several imaging modalities displays improved predictive performance, which may enhance patient outcomes, based on direct personalized therapeutic options. However, clinicians and researchers must address existing limitations, conduct randomized controlled trials, and consider the ethical and legal aspects that arise to establish AI as a standard decision-support tool. Conclusions: AI applications may result in substantial advances in EC management, heralding a new era. Considering the complexity of EC as a clinical entity, the evolving potential of AI is anticipated to ameliorate patients' quality of life and survival rates.

Keywords: artificial intelligence; diagnosis; esophageal cancer; prognosis; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart of study selection.

References

    1. Collaborators CBDOC The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: A systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol. Hepatol. 2020;5:582–597. doi: 10.1016/S2468-1253(20)30007-8. - DOI - PMC - PubMed
    1. Liu C.Q., Ma Y.L., Qin Q., Wang P.H., Luo Y., Xu P.F., Cui Y. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. Thorac. Cancer. 2023;14:3–11. doi: 10.1111/1759-7714.14745. - DOI - PMC - PubMed
    1. Arnold M., Laversanne M., Brown L.M., Devesa S.S., Bray F. Predicting the Future Burden of Esophageal Cancer by Histological Subtype: International Trends in Incidence up to 2030. Am. J. Gastroenterol. 2017;112:1247–1255. doi: 10.1038/ajg.2017.155. - DOI - PubMed
    1. American Cancer Society . Cancer Facts & Figures 2024. American Cancer Society; Atlanta, GA, USA: 2024.
    1. Global Burden of Disease Cancer Collaboration. Fitzmaurice C., Allen C., Barber R.M., Barregard L., Bhutta Z.A., Brenner H., Dicker D.J., Chimed-Orchir O., Dandona R., et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524–548. doi: 10.1001/jamaoncol.2017.0098. Erratum in JAMA Oncol. 2017, 3, 418. - DOI - PMC - PubMed

LinkOut - more resources